"Spreading import entry points for drugs and medical devices inland can improve supply chains but strains regulatory capacity." Critically examine.

Drugs, medical devices and cosmetics can be imported only through notified ports of entry. The Union Health Ministry has proposed 10 new ones to ease imports: 8 Inland Container Depots (ICDs), SEZ Bommasandra and Noida International Airport [1]. The logistics gain is real, but it lasts only if regulatory capacity grows with it.

How inland entry points strengthen supply chains

• Clearance near clusters: ICDs at Sonipat and Dadri (NCR), Sanath Nagar and Thimmapur (Hyderabad) and Whitefield (Bengaluru) bring customs closer to pharma and medtech hubs. This cuts transit time and cost for imported APIs and components [1].
• Faster air imports: Noida International Airport is earmarked for drug imports by air, which suits high-value, time-sensitive consignments [1].
• Resilience: more gateways ease congestion at a few seaports and lower the risk of stock-outs of critical medicines and devices.

How they strain regulatory capacity

• Thin staffing: every port needs CDSCO officers to check papers and draw samples. A Rajya Sabha committee flagged a shortage of drug inspectors and inadequate testing facilities in 2008 [2]. In 2026 the Health Standing Committee said Drugs Controller vacancies still slow CDSCO's work [3].
• Testing bottleneck: quality is confirmed in labs, not at the gate. Scattered inland samples mean longer turnaround times.
• Quality risk: if checks become uneven, more entry points give substandard or falsified products more ways in.
• Centre–State gap: once goods are on sale, state drug controllers enforce quality, and their capacity varies. The 2008 report also noted weak Centre–State coordination [2].
• Policy tension: cheaper imports may hurt bulk-drug and device plants under the PLI scheme that are still scaling up [4].

Way forward

• Open a port only after its regulatory staff are posted, and fill vacancies on a time-bound basis [3].
• Empanel accredited public and private labs near ICD clusters [3].
• Use risk-based, digital clearance linked with Customs.
• Tie easier logistics to PLI milestones so that import dependence stays temporary [4].

Inland entry points modernise health-product logistics, but a port without inspectors only moves the delay elsewhere. If people and labs come first and notification follows, India can secure both access and quality. That serves SDG 3 and the Article 47 duty to improve public health.